Core Viewpoint - Perrigo Company is facing a class action lawsuit due to allegations of misleading investors about the value of its infant formula business, which has resulted in significant financial repercussions for the company [1][3]. Summary by Sections Company Overview - Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally [1]. Class Action Details - The class period for the lawsuit is from February 27, 2024, to November 4, 2025 [1]. - The lawsuit was filed on behalf of all investors who acquired Perrigo securities during the class period [1]. Allegations - The complaint alleges that Perrigo failed to disclose several critical issues regarding its infant formula business: 1. Significant underinvestment in maintenance, operational improvements, and repairs [3]. 2. The need for substantial capital and operational expenditures beyond previously stated cost estimates to remediate the business [3]. 3. Significant manufacturing deficiencies in the infant formula facility [3]. 4. Overstated financial results, including earnings and cash flow, due to the above issues [3]. Financial Impact - On November 5, 2025, Perrigo announced disappointing financial results for Q3 2025, leading to a reduction in its fiscal year 2025 outlook primarily due to dynamics in the infant formula industry [4]. - The company is initiating a strategic review of its infant formula business and reassessing a previously announced investment of $240 million in this area [4]. - Following this announcement, Perrigo's stock price fell by $5.09, or 25.2%, closing at $15.10 per share on November 5, 2025 [4].
PRGO Class Action Reminder: Perrigo Company Stockholders Should Contact Robbins LLP for Information About Leading the Class Action Against PRGO